Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patient population

Patient no.	Age, y	Major clinical manifestations	Prior therapy
1	37	Mucosal ulcerations, dermatitis anemia, thrombocytopenia, splenomegaly	Prednisone, hydroxyurea, IFN-α, anti-IL-5 antibody (SCH55700)
2	51	Mucosal ulcerations, dermatitis, splenomegaly	Prednisone, hydroxyurea, IFN-α, anti-IL-5 antibody (SCH55700)
3	47	Pulmonary fibrosis, dermatitis, splenomegaly	None
4	36	Splenomegaly	Hydroxyurea
5	47	Endomyocardial fibrosis, pulmonary fibrosis, dermatitis, splenomegaly	Prednisone, hydroxyurea, IFN-α, cyclosporin A
6	29	Endomyocardial fibrosis, peripheral neuropathy, splenomegaly	Prednisone, hydroxyurea
7	33	Endomyocardial fibrosis, hepatosplenomegaly	Imatinib mesylate (100 mg daily)
8	30	Myocarditis, sinusitis, obstructive pulmonary disease, splenomegaly	Prednisone, hydroxyurea

Patient no.	Age, y	Major clinical manifestations	Prior therapy
1	37	Mucosal ulcerations, dermatitis anemia, thrombocytopenia, splenomegaly	Prednisone, hydroxyurea, IFN-α, anti-IL-5 antibody (SCH55700)
2	51	Mucosal ulcerations, dermatitis, splenomegaly	Prednisone, hydroxyurea, IFN-α, anti-IL-5 antibody (SCH55700)
3	47	Pulmonary fibrosis, dermatitis, splenomegaly	None
4	36	Splenomegaly	Hydroxyurea
5	47	Endomyocardial fibrosis, pulmonary fibrosis, dermatitis, splenomegaly	Prednisone, hydroxyurea, IFN-α, cyclosporin A
6	29	Endomyocardial fibrosis, peripheral neuropathy, splenomegaly	Prednisone, hydroxyurea
7	33	Endomyocardial fibrosis, hepatosplenomegaly	Imatinib mesylate (100 mg daily)
8	30	Myocarditis, sinusitis, obstructive pulmonary disease, splenomegaly	Prednisone, hydroxyurea